The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells

Leukemia

Volumn 26, Issue 6, 2012, Pages 1301-1312

  Zucchetto, A ^a   Vaisitti, T ^b   Benedetti, D ^a   Tissino, E ^a   Bertagnolo, V ^c   Rossi, D ^d   Bomben, R ^a   Dal Bo, M ^a   Del Principe, M I ^e   Gorgone, A ^f   Pozzato, G ^g   Gaidano, G ^d   Del Poeta, G ^e   Malavasi, F ^b   Deaglio, S ^b   Gattei, V ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY OF TRIESTE   (Italy)

Author keywords

CD38; CD49d; chronic lymphocytic leukemia; CLL; integrins

Indexed keywords

ALPHA4 INTEGRIN; BETA1 INTEGRIN; CD38 ANTIGEN; F ACTIN; FIBRONECTIN; HETERODIMER; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL ADHESION; CELL SHAPE; CELL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL; LIPID RAFT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION;

EID: 84862016635     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.369     Document Type: Article

References (48)

1. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003; 123: 380-388. (Pubitemid 37363477)
2. Scielzo C, Ten HE, Bertilaccio MT, Muzio M, Calissano C, Ghia P et al. How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection. Leuk Lymphoma 2010; 51: 1371-1374.
3. Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, Tamagnone L et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005; 105: 3042-3050.
4. Deaglio S, Vaisitti T, Zucchetto A, Gattei V, Malavasi F. CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. Semin Cancer Biol 2010; 20: 416-423.
5. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal BM, Marconi D et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009; 69: 4001-4009.
6. Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008; 111: 865-873.
7. Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C et al. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica 2008; 93: 1575-1579.
8. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008; 140: 537-546. (Pubitemid 351230080)
9. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847. (Pubitemid 29430399)
10. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633-2639.
11. de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, Garcia-Marco J et al. Engagement of {alpha}4{beta}1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 2002; 71: 495-502.
12. Eksioglu-Demiralp E, Alpdogan O, Aktan M, Firatli T, Ozturk A, Budak T et al. Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages. Leukemia 1996; 10: 1331-1339. (Pubitemid 26261430)
13. Ruoslahti E. Integrins. J Clin Invest 1991; 87: 1-5.
14. Verdone G, Doliana R, Corazza A, Colebrooke SA, Spessotto P, Bot S et al. The solution structure of EMILIN1 globular C1q domain reveals a disordered insertion necessary for interaction with the alpha4beta1 integrin 2. J Biol Chem 2008; 283: 18947-18956.
15. Rose DM, Han J, Ginsberg MH. Alpha4 integrins and the immune response. Immunol Rev 2002; 186: 118-124.
16. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008; 88: 841-886.
17. Deaglio S, Mallone R, Baj G, Arnulfo A, Surico N, Dianzani U et al. CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. Chem Immunol 2000; 75: 99-120. (Pubitemid 30088771)
18. Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 1998; 160: 395-402. (Pubitemid 28116754)
19. Frasca L, Fedele G, Deaglio S, Capuano C, Palazzo R, Vaisitti T et al. CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. Blood 2006; 107: 2392-2399. (Pubitemid 43345559)
20. Zubiaur M, Fernandez O, Ferrero E, Salmeron J, Malissen B, Malavasi F et al. CD38 is associated with lipid rafts and upon receptor stimulation leads to Akt/protein kinase B and Erk activation in the absence of the CD3-zeta immune receptor tyrosine-based activation motifs. J Biol Chem 2002; 277: 13-22. (Pubitemid 34952022)
21. Morra M, Zubiaur M, Terhorst C, Sancho J, Malavasi F. CD38 is functionally dependent on the TCR/CD3 complex in human T cells. FASEB J 1998; 12: 581-592. (Pubitemid 28183517)
22. Deaglio S, Vaisitti T, Billington R, Bergui L, Omede P, Genazzani AA et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood 2007; 109: 5390-5398. (Pubitemid 46890561)
23. Deaglio S, Zubiaur M, Gregorini A, Bottarel F, Ausiello CM, Dianzani U et al. Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. Blood 2002; 99: 2490-2498. (Pubitemid 34586752)
24. Zilber MT, Setterblad N, Vasselon T, Doliger C, Charron D, Mooney N et al. MHC class II/CD38/CD9: a lipid-raft-dependent signaling complex in human monocytes. Blood 2005; 106: 3074-3081. (Pubitemid 41565903)
25. Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006; 108: 1135-1144. (Pubitemid 44232007)
26. Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010; 24: 958-969.
27. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001; 114: 4143-4151. (Pubitemid 33138652)
28. Buggins AG, Levi A, Gohil S, Fishlock K, Patten PE, Calle Y et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 2011; 154: 216-222.
29. Matutes E, Owusu-Ankomah K, Morilla R, Garcia MJ, Houlihan A, Que TH et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640-1645. (Pubitemid 24323778)
30. Bomben R, Dal Bo M, Capello D, Benedetti D, Marconi D, Zucchetto A et al. Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood 2007; 109: 2989-2998. (Pubitemid 46482099)
31. Zucchetto A, Sonego P, Degan M, Bomben R, Dal Bo M, Russo S et al. Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. J Cell Physiol 2005; 204: 113-123. (Pubitemid 40776813)
32. Zucchetto A, Bomben R, Dal Bo M, Bulian P, Benedetti D, Nanni P et al. CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. Leukemia 2006; 20: 523-525. (Pubitemid 43291756)
33. Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102: 2146-2155. (Pubitemid 37122392)
34. Bustelo XR. Vav proteins, adaptors and cell signaling. Oncogene 2001; 20: 6372-6381. (Pubitemid 32977845)
35. Nobes CD, Hall A. Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995; 81: 53-62.
36. Koopman G, Keehnen RM, Lindhout E, Newman W, Shimizu Y, van Seventer GA et al. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 1994; 152: 3760-3767. (Pubitemid 24111046)
37. Nuckel H, Switala M, Collins CH, Sellmann L, Grosse-Wilde H, Duhrsen U et al. High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clin Immunol 2009; 131: 472-480.
38. Buggins AG, Pepper C, Patten PE, Hewamana S, Gohil S, Moorhead J et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res 2010; 70: 7523-7533.
39. Jacobson K, Mouritsen OG, Anderson RG. Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol 2007; 9: 7-14. (Pubitemid 46024188)
40. Hemler ME. Integrin associated proteins. Curr Opin Cell Biol 1998; 10: 578-585. (Pubitemid 28477015)
41. Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002; 110: 599-611. (Pubitemid 35247840)
42. Feigelson SW, Grabovsky V, Shamri R, Levy S, Alon R. The CD81 tetraspanin facilitates instantaneous leukocyte VLA-4 adhesion strengthening to vascular cell adhesion molecule 1 (VCAM-1) under shear flow. J Biol Chem 2003; 278: 51203-51212. (Pubitemid 38020357)
43. Bertagnolo V, Brugnoli F, Mischiati C, Sereni A, Bavelloni A, Carini C et al. Vav promotes differentiation of human tumoral myeloid precursors. Exp Cell Res 2005; 306: 56-63. (Pubitemid 40692771)
44. Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, Bonello L et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007; 110: 4012-4021. (Pubitemid 350248457)
45. Congleton J, Jiang H, Malavasi F, Lin H, Yen A. ATRA-induced HL-60 myeloid leukemia cell differentiation depends on the CD38 cytosolic tail needed for membrane localization, but CD38 enzymatic activity is unnecessary. Exp Cell Res 2010; 317: 910-919.
46. Ferrarini M, Chiorazzi N. Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia. Semin Hematol 2004; 41: 207-223. (Pubitemid 38953164)
47. Till KJ, Lin K, Zuzel M, Cawley JC. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 2002; 99: 2977-2984. (Pubitemid 34525388)
48. Vigorito E, Gambardella L, Colucci F, McAdam S, Turner M. Vav proteins regulate peripheral B-cell survival. Blood 2005; 106: 2391-2398. (Pubitemid 41510812)